Cargando…

Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection

There is limited high-quality evidence to guide the optimal treatment of Mycobacterium kansasii pulmonary disease. We retrospectively collected clinical data from 33 patients with M. kansasii pulmonary disease to determine the time-to-sputum culture conversion (SCC) upon treatment with a standard co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Srivastava, Shashikant, Boorgula, Gunavanthi D., Wang, Jann-Yuan, Huang, Hung-Ling, Howe, Dave, Gumbo, Tawanda, Heysell, Scott K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017304/ https://www.ncbi.nlm.nih.gov/pubmed/35315686 http://dx.doi.org/10.1128/aac.02320-21

Ejemplares similares

Comparison of Rifamycins for Efficacy Against Mycobacterium avium Complex and Resistance Emergence in the Hollow Fiber Model System
por: Boorgula, Gunavanthi D., et al.
Publicado: (2021)

Novel Short-Course Therapy and Morphism Mapping for Clinical Pulmonary Mycobacterium kansasii
por: Srivastava, Shashikant, et al.
Publicado: (2021)

Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2016)

Comment on “Long-term Safety and Tolerability of Omadacycline for the Treatment of Mycobacterium abscessus Infections”
por: Srivastava, Shashikant, et al.
Publicado: (2023)

Safety and tolerability of long-term use of omadacycline in the treatment of Mycobacterium abscessus infections
por: Srivastava, Shashikant, et al.
Publicado: (2023)

Cefdinir and β-Lactamase Inhibitor Independent Efficacy Against Mycobacterium tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2021)

Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis
por: Alffenaar, Jan-Willem C, et al.
Publicado: (2020)

Repurposing Cefazolin-Avibactam for the Treatment of Drug Resistant Mycobacterium tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2021)

Pharmacodynamic Biomarkers for Quantifying the Mycobacterial Effect of High Doses of Rifampin in Patients with Rifampin-susceptible Pulmonary Tuberculosis
por: Said, Bibie N, et al.
Publicado: (2021)

1697. Dose-response Studies of the Novel Bacterial Leucyl-tRNA Synthetase Inhibitor, Epetraborole, in the Intracellular Hollow Fiber System Model of Mycobacterium avium complex Lung Disease
por: Chapagain, Moti, et al.
Publicado: (2022)

Effect of specimen processing, growth supplement, and different metabolic population on Mycobacterium tuberculosis laboratory diagnosis
por: Srivastava, Shashikant, et al.
Publicado: (2020)

Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases
por: Deshpande, Devyani, et al.
Publicado: (2016)

Omadacycline efficacy in the hollow fibre system model of pulmonary Mycobacterium avium complex and potency at clinically attainable doses
por: Chapagain, Moti, et al.
Publicado: (2022)

Determining the Delamanid Pharmacokinetics/Pharmacodynamics Susceptibility Breakpoint Using Monte Carlo Experiments
por: Liu, Yongge, et al.
Publicado: (2023)

Evaluation of Ceftriaxone Plus Avibactam in an Intracellular Hollow Fiber Model of Tuberculosis: Implications for the Treatment of Disseminated and Meningeal Tuberculosis in Children
por: Srivastava, Shashikant, et al.
Publicado: (2020)

Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating Mycobacterium tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2021)

Pharmacokinetic-Pharmacodynamic Determinants of Clinical Outcomes for Rifampin-Resistant Tuberculosis: A Multisite Prospective Cohort Study
por: Heysell, Scott K, et al.
Publicado: (2022)

Mycobacterium kansasii Pulmonary Diseases in Korea
por: Yim, Jae-Joon, et al.
Publicado: (2005)

Pleural Effusion/Empyema With Mycobacterium kansasii
por: Luttmann, Kelly F, et al.
Publicado: (2022)

1659. Pharmacokinetics/pharmacodynamics of the Novel Gyrase Inhibitor SPR719/SPR720 and Clinical Dose Selection to Treat Pulmonary Mycobacterium avium-complex Disease
por: Deshpande, Devyani, et al.
Publicado: (2020)

Minocycline intra-bacterial pharmacokinetic hysteresis as a basis for pharmacologic memory and a backbone for once-a-week pan-tuberculosis therapy
por: Deshpande, Devyani, et al.
Publicado: (2022)

A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground
por: Srivastava, Shashikant, et al.
Publicado: (2016)

Aislamiento e identificación de mycobacterium kansasii
por: Vicente Mojica, Aurora
Publicado: (1995)

Mycobacterium kansasii osteomyelitis – a masquerading disease
por: Bhatt, Kiranmai, et al.
Publicado: (2018)

Laryngeal Inflammatory Pseudotumour Secondary to Mycobacterium kansasii
por: Al-Zahid, Saif, et al.
Publicado: (2018)

Therapy for Mycobacterium kansasii Infection: Beyond 2018
por: DeStefano, Michelle S., et al.
Publicado: (2018)

Genomic Insights Into the Mycobacterium kansasii Complex: An Update
por: Jagielski, Tomasz, et al.
Publicado: (2020)

A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies
por: Srivastava, Shashikant, et al.
Publicado: (2016)

Insights on the Emergence of Mycobacterium tuberculosis from the Analysis of Mycobacterium kansasii
por: Wang, Joyce, et al.
Publicado: (2015)

Determination of Clinical Characteristics of Mycobacterium kansasii-Derived Species by Reanalysis of Isolates Formerly Reported as M. kansasii
por: Kim, Young-gon, et al.
Publicado: (2021)

Mycobacterium tuberculosis sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration
por: Gumbo, Tawanda, et al.
Publicado: (2021)

Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy development
por: Gumbo, Tawanda, et al.
Publicado: (2023)

Mycobacterium Kansasii Infection and Microscopic Polyangiitis: An Unexpected Association
por: Alnaser, Ammar, et al.
Publicado: (2018)

Draft Genome Sequences of Mycobacterium kansasii Clinical Strains
por: Borówka, Paulina, et al.
Publicado: (2017)

Osteomyelitis due to Mycobacterium kansasii in a patient with sarcoidosis
por: van Herwaarden, N., et al.
Publicado: (2017)

Systemic Mycobacterium kansasii Infection in Two Related Cats
por: Černá, Petra, et al.
Publicado: (2020)

Prosthetic Knee Joint Infection Caused by Mycobacterium kansasii
por: Dasari, Suhas P., et al.
Publicado: (2022)

The Combination of Rifampin plus Moxifloxacin Is Synergistic for Suppression of Resistance but Antagonistic for Cell Kill of Mycobacterium tuberculosis as Determined in a Hollow-Fiber Infection Model
por: Drusano, G. L., et al.
Publicado: (2010)

Gepotidacin Pharmacokinetics-Pharmacodynamics against Escherichia coli in the One-Compartment and Hollow-Fiber In Vitro Infection Model Systems
por: VanScoy, Brian D., et al.
Publicado: (2021)

2569. Pharmacokinetic-Pharmacodynamic Evaluation of Sulopenem Using a Five-Day Hollow-Fiber In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ppinsk9d5tnoqngtdmjfsj4l9v